Considerations in glaucoma therapy: fixed combinations versus their component medications

Eve J HigginbothamMorehouse School of Medicine, Atlanta, GA, USAAbstract: Fixed combinations of medications that lower intraocular pressure (IOP) are increasingly used in the treatment of glaucoma and ocular hypertension and offer several potential advantages over combined use of the separate compon...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Eve J Higginbotham
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/fe8a345a180446ccb35114a20e389d07
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fe8a345a180446ccb35114a20e389d07
record_format	dspace
spelling	oai:doaj.org-article:fe8a345a180446ccb35114a20e389d072021-12-02T02:43:56ZConsiderations in glaucoma therapy: fixed combinations versus their component medications1177-54671177-5483https://doaj.org/article/fe8a345a180446ccb35114a20e389d072009-12-01T00:00:00Zhttp://www.dovepress.com/considerations-in-glaucoma-therapy-fixed-combinations-versus-their-com-a3838https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Eve J HigginbothamMorehouse School of Medicine, Atlanta, GA, USAAbstract: Fixed combinations of medications that lower intraocular pressure (IOP) are increasingly used in the treatment of glaucoma and ocular hypertension and offer several potential advantages over combined use of the separate component medications including enhanced convenience, improved adherence, reduced exposure to preservatives, and possible cost savings. This review aims to examine the current role of IOP-lowering fixed combinations in disease management. The results of studies that compared the efficacy and safety of IOP-lowering fixed combinations with their component medications are summarized, including those fixed combinations that consist of a prostaglandin analog and timolol. The fixed combinations currently available for use in the United States are fixed-combination dorzolamide/timolol (FCDT) and fixed-combination brimonidine/timolol (FCBT). Both of these fixed combinations reduce IOP more effectively than their component medications used separately as monotherapy. FCBT therapy also demonstrates a more favorable safety profile and reduced ocular allergy compared to monotherapy with brimonidine, a component medication. Few studies have directly compared the efficacy and safety of FCDT and FCBT, but available evidence suggests that FCBT is at least as effective as FCDT in lowering IOP and is more comfortable and better tolerated. Additional studies are needed to further evaluate the comparative efficacy and tolerability of FCDT and FCBT in the management of glaucoma and ocular hypertension.Keywords: glaucoma, intraocular pressure, fixed combination, adherence, brimonidine Eve J HigginbothamDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 1-9 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Eve J Higginbotham Considerations in glaucoma therapy: fixed combinations versus their component medications
description	Eve J HigginbothamMorehouse School of Medicine, Atlanta, GA, USAAbstract: Fixed combinations of medications that lower intraocular pressure (IOP) are increasingly used in the treatment of glaucoma and ocular hypertension and offer several potential advantages over combined use of the separate component medications including enhanced convenience, improved adherence, reduced exposure to preservatives, and possible cost savings. This review aims to examine the current role of IOP-lowering fixed combinations in disease management. The results of studies that compared the efficacy and safety of IOP-lowering fixed combinations with their component medications are summarized, including those fixed combinations that consist of a prostaglandin analog and timolol. The fixed combinations currently available for use in the United States are fixed-combination dorzolamide/timolol (FCDT) and fixed-combination brimonidine/timolol (FCBT). Both of these fixed combinations reduce IOP more effectively than their component medications used separately as monotherapy. FCBT therapy also demonstrates a more favorable safety profile and reduced ocular allergy compared to monotherapy with brimonidine, a component medication. Few studies have directly compared the efficacy and safety of FCDT and FCBT, but available evidence suggests that FCBT is at least as effective as FCDT in lowering IOP and is more comfortable and better tolerated. Additional studies are needed to further evaluate the comparative efficacy and tolerability of FCDT and FCBT in the management of glaucoma and ocular hypertension.Keywords: glaucoma, intraocular pressure, fixed combination, adherence, brimonidine
format	article
author	Eve J Higginbotham
author_facet	Eve J Higginbotham
author_sort	Eve J Higginbotham
title	Considerations in glaucoma therapy: fixed combinations versus their component medications
title_short	Considerations in glaucoma therapy: fixed combinations versus their component medications
title_full	Considerations in glaucoma therapy: fixed combinations versus their component medications
title_fullStr	Considerations in glaucoma therapy: fixed combinations versus their component medications
title_full_unstemmed	Considerations in glaucoma therapy: fixed combinations versus their component medications
title_sort	considerations in glaucoma therapy: fixed combinations versus their component medications
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/fe8a345a180446ccb35114a20e389d07
work_keys_str_mv	AT evejhigginbotham considerationsinglaucomatherapyfixedcombinationsversustheircomponentmedications
_version_	1718402201300238336

Considerations in glaucoma therapy: fixed combinations versus their component medications

Ejemplares similares